There’s always ‘Tesaro’: antibody bet brings $17M up front to Anaptysbio
Anaptysbio Inc.’s SHM-XEL antibody-making platform that replicates somatic hypermutation in vitro drew yet another partner, this time Tesaro Inc., which agreed to pay $17 million up front for rights to three cancer antibody programs and could fork over as much as $108 million per target.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST